At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,076 enrolled
Drug / intervention
Acyclovir 5 percent (Perrigo) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
In Brief
A Phase 3 clinical trial evaluating Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), and 1 other intervention for Herpes Labialis. Completed, enrolled 4,076 participants across 1 site.
Detailed Summary
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Labialis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionApr 2016
Study CompletionNov 2017
TodayJul 2026
First PostedOct 16, 2014
Enrollment StartOct 6, 2014
Primary CompletionApr 27, 2016
Study CompletionNov 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.7 years ago
Interventions
Acyclovir 5 percent (Perrigo)drug
Acyclovir 5 percent (Reference)drug
Placebo creamdrug